Davis Polk advised the underwriters in connection with the offering. BioXcel Therapeutics, Inc. completed the offering of 4,000,000 shares of its common stock. The common stock…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now